Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download 4.1 MB pdf)
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)